Department of Oncology, Ganyu District People's Hospital of Lianyungang City, Lianyungang, Jiangsu, China.
Cancer Institute, The Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China.
J Am Med Dir Assoc. 2023 Jul;24(7):937-944.e3. doi: 10.1016/j.jamda.2023.03.032. Epub 2023 May 5.
To evaluate the impact of prefrailty and frailty on all-cause mortality, acute exacerbation, and all-cause hospitalization in patients with chronic obstructive pulmonary disease (COPD).
Meta-analysis.
Two authors independently searched PubMed, Web of Science, and Embase databases until December 27, 2022,to identify studies that reported the predictive value of prefrailty and frailty in COPD patients.
All-cause mortality, acute exacerbation, and all-cause hospitalization.
Ten studies reporting on 11 articles enrolling 13,203 patients with COPD were included. The prevalence of frailty ranged from 6.0% to 51%. When compared with nonfrailty, the pooled adjusted hazard ratio (HR) of all-cause mortality was 1.48 (95% CI 0.92-2.40) for prefrailty and 2.64 (95% CI 1.74-4.02) for frailty, respectively. The pooled adjusted odds ratio (OR) of all-cause hospitalization was 1.35 (95% CI 1.05-1.74) for prefrailty and 1.65 (95% CI 1.05-2.61) for frailty. In addition, frailty significantly predicted all acute exacerbation (OR 2.20, 95% CI 1.26-3.81) but not moderate to severe acute exacerbation (OR 1.42, 95% CI 0.94-2.17) in patients with stable COPD. However, the pooled results of all-cause hospitalization were not reliable in leave-1-out sensitivity analyses.
Frailty significantly predicts all-cause mortality in patients with COPD, even after adjustment for common confounding factors. Assessment of frail status in COPD patients may improve secondary prevention and allow early intervention. However, future studies are warranted to validate the impact of frailty defined by a standardized definition of frailty on acute exacerbation and all-cause hospitalization.
评估衰弱前期和衰弱对慢性阻塞性肺疾病(COPD)患者全因死亡率、急性加重和全因住院的影响。
荟萃分析。
两位作者独立检索 PubMed、Web of Science 和 Embase 数据库,直到 2022 年 12 月 27 日,以确定报告衰弱前期和衰弱在 COPD 患者中的预测价值的研究。
全因死亡率、急性加重和全因住院。
纳入了 10 项研究,共纳入了 13203 例 COPD 患者的 11 篇文章。衰弱的患病率从 6.0%到 51%不等。与非衰弱相比,衰弱前期和衰弱的全因死亡率的合并调整后的危险比(HR)分别为 1.48(95%可信区间 0.92-2.40)和 2.64(95%可信区间 1.74-4.02)。衰弱前期和衰弱的全因住院的合并调整后的优势比(OR)分别为 1.35(95%可信区间 1.05-1.74)和 1.65(95%可信区间 1.05-2.61)。此外,衰弱前期显著预测所有急性加重(OR 2.20,95%可信区间 1.26-3.81),但不能预测稳定期 COPD 患者的中重度急性加重(OR 1.42,95%可信区间 0.94-2.17)。然而,在单因素敏感性分析中,全因住院的合并结果并不可靠。
衰弱前期显著预测 COPD 患者的全因死亡率,即使在调整了常见混杂因素后也是如此。在 COPD 患者中评估虚弱状态可能有助于二级预防和早期干预。然而,需要进一步的研究来验证使用衰弱的标准化定义来定义的衰弱对急性加重和全因住院的影响。